Jay Flatley

Jay joined the Iridia Board of Directors in August 2017 and serves as Director and Chairman of the Board.

In addition, Jay is Chairman of the Board of Directors of Illumina. He led Illumina as CEO from 1999 until 2016, as Executive Chairman through 2019. During his tenure as CEO, he took the company from $1.3 million in sales in 2000 to $2.2 billion in 2015, representing a compound annual growth rate of 64 percent. He oversaw the company’s expansion from microarrays into next-generation sequencing with the acquisition of Solexa in 2006, and from research into clinical and applied markets. Under his leadership, Illumina was named multiple times to the Deloitte & Touche Fast 50 and Fast 500 lists, as well as to the Forbes 25 Fastest-Growing Tech Companies (2007, 2009 and 2010), the Fortune 100 Fastest-Growing Companies (2010 and 2011) lists, and recognition by MIT Technology Review as the World’s Smartest Company in 2014.

Currently, Jay serves on the Boards of Directors at Coherent and Denali; Board of Trustees at The Salk Institute; Lead Independent Director at Zymergen and Chair at Wellcome Leap. Previously, he served as CEO of Molecular Dynamics which was successfully acquired by Amersham (GE Healthcare).

Jay received a B.A. in economics from Claremont McKenna College and a B.S. and M.S. (summa cum laude) in industrial engineering from Stanford University.